<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Hypertens</journal-id><journal-id journal-id-type="iso-abbrev">Clin Hypertens</journal-id><journal-title-group><journal-title>Clinical Hypertension</journal-title></journal-title-group><issn pub-type="epub">2056-5909</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29507752</article-id><article-id pub-id-type="pmc">5831582</article-id><article-id pub-id-type="publisher-id">89</article-id><article-id pub-id-type="doi">10.1186/s40885-018-0089-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Chlorthalidone, not hydrochlorothiazide, is the right diuretic for comparison</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6745-9391</contrib-id><name><surname>Mehta</surname><given-names>Ravi Tejraj</given-names></name><address><email>ravi.mehta@ipca.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Pareek</surname><given-names>Anil</given-names></name><address><email>anil.pareek@ipca.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Purkait</surname><given-names>Indranil</given-names></name><address><email>indranil.purkait@ipca.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1766 8461</institution-id><institution-id institution-id-type="GRID">grid.464923.e</institution-id><institution>Ipca Laboratories Limited, </institution></institution-wrap>Mumbai, India </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>24</volume><elocation-id>4</elocation-id><history><date date-type="received"><day>8</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>19</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">We have read the study design &#x0201c;Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active controlled, phase 4, randomized trial&#x0201d; by Oh GC, et al. with interest. The authors aim to compare the efficacy of amlodipine or hydrochlorothiazide (HCTZ) with an ARB. However, we wish to highlight that chlorthalidone (CTD) is the evidence-based and recommended anti-hypertensive diuretic, and should replace HCTZ in the trial to effectively compare efficacy against the CCB amlodipine.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chlorthalidone</kwd><kwd>Hydrochlorothiazide</kwd><kwd>Amlodipine</kwd><kwd>Hypertension</kwd><kwd>Thiazide diuretics</kwd><kwd>Calcium channel blockers</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par16">Dear Editor.</p><p id="Par17">We have read with interest the study design by Oh GC, et al. [<xref ref-type="bibr" rid="CR1">1</xref>]. The authors aim to compare the efficacy of combination of calcium channel blocker (CCB) or thiazide diuretic with an angiotensin receptor blocker (ARB). However, we wish to highlight that instead of hydrochlorothiazide (HCTZ), chlorthalidone (CTD) is the evidence-based anti-hypertensive diuretic and should be used to effectively compare efficacy against the CCB amlodipine.<list list-type="order"><list-item><p id="Par18">CTD is structurally and pharmacokinetically distinct from HCTZ with a much longer half-life (40&#x02013;60&#x000a0;h vs. 3.2&#x02013;13.1&#x000a0;h) and a wider volume of distribution. Hence, comparing HCTZ to amlodipine (half-life 38-50&#x000a0;h), with such disparity in half-lives, can lead to unsurprising differences in favour of amlodipine. CTD has unique pleiotropic properties, not shared by HCTZ, like inhibition of platelet aggregation and promotion of angiogenesis [<xref ref-type="bibr" rid="CR2">2</xref>]. These features impart CTD a unique advantage to effectively lower BP as well as improve cardiovascular (CV) outcomes in hypertension [<xref ref-type="bibr" rid="CR3">3</xref>].</p></list-item><list-item><p id="Par19">CTD has been employed in several major National Institutes of Health (NIH)-funded randomized controlled trials evaluating hard outcomes: the Hypertension Detection and Follow-Up Program (HDFP), Multiple Risk Factor Intervention Trial (MRFIT), Systolic Hypertension in the Elderly Program (SHEP) and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT); and has been repeatedly shown to reduce CV morbidity and mortality at clinically used doses. On the other hand, HCTZ at the usual prescribed doses (12.5-25&#x000a0;mg/day) has been called a &#x0201c;paltry&#x0201d; antihypertensive, inferior to all other drug classes, and with no published evidence of reducing CV events [<xref ref-type="bibr" rid="CR4">4</xref>]. Major global hypertension guidelines including latest ones by ACC/AHA [<xref ref-type="bibr" rid="CR5">5</xref>], CHEP [<xref ref-type="bibr" rid="CR6">6</xref>] and NICE [<xref ref-type="bibr" rid="CR7">7</xref>] recommend preferring chlorthalidone (thiazide-like diuretics) over HCTZ and bendroflumethiazide.</p></list-item><list-item><p id="Par20">The authors have listed measurements of ambulatory pulse wave velocity (PWV), and augmentation index (AIx) as secondary endpoints. In a recent randomized, prospective cross-over study, effects of CTD 12.5&#x000a0;mg vs. HCTZ 25&#x000a0;mg, both in combination with ARB (Candesartan 8&#x000a0;mg), on PWV and AIx were compared. After 8&#x000a0;weeks, CTD arm showed a significant reduction in PWV vs. baseline (<italic>p</italic>&#x02009;=&#x02009;0.007) and HCTZ (<italic>p</italic>&#x02009;=&#x02009;0.033) [<xref ref-type="bibr" rid="CR8">8</xref>].</p></list-item><list-item><p id="Par21">In the MRFIT, in the nine clinics where HCTZ was prescribed predominantly initially, there was a 44% higher CHD mortality, whereas the trend of mortality was favorable in the six clinics that primarily used CTD. It was recommended and accepted by the MRFIT Steering Committee to switch all participants from HCTZ to CTD. Later, with CTD, the mortality trend was reversed and the same group had a 28% lower risk [<xref ref-type="bibr" rid="CR9">9</xref>]. Similarly, it has been suggested that the findings of Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial would have been much more compelling had CTD been the agent selected for the diuretic-based regimen [<xref ref-type="bibr" rid="CR10">10</xref>].</p></list-item><list-item><p id="Par22">In a randomized, multicenter trial, we found losartan/CTD combination to be as effective as losartan/HCTZ in lowering office BP and was well tolerated [<xref ref-type="bibr" rid="CR11">11</xref>]. In another recent study, we compared CTD with HCTZ by 24-h ambulatory BP monitoring and found that CTD significantly reduced 24-h ABP as well as daytime and nighttime BP. However, no significant 24-h ABP reduction was seen with HCTZ, which merely converted sustained hypertension into masked hypertension [<xref ref-type="bibr" rid="CR12">12</xref>].</p></list-item><list-item><p id="Par23">CCBs have been shown to be better at reducing central BP and arterial stiffness than thiazide-type diuretics leading the authors to hypothesize that CCB-based combination will be associated with better CV outcomes. However, in ALLHAT study, substantially higher risk of heart failure with amlodipine was found compared to CTD (RR 1.38; 95% CI, 1.25-1.52); risk being even higher in patients with diabetes (RR 1.42; 95% CI, 1.23-1.64) [<xref ref-type="bibr" rid="CR13">13</xref>]. Thus, the CV outcome of the two combinations must be assessed in a long-term study.</p></list-item></list></p><p id="Par24">To summarize, we urge the authors to re-think on the choice of HCTZ as the comparator diuretic and replace it with CTD, if feasible.</p></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACC/AHA</term><def><p id="Par2">American College of Cardiology/American Heart Association</p></def></def-item><def-item><term>AIx</term><def><p id="Par3">Augmentation index</p></def></def-item><def-item><term>ALLHAT</term><def><p id="Par4">Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial</p></def></def-item><def-item><term>ARB</term><def><p id="Par5">Angiotensin receptor blocker</p></def></def-item><def-item><term>CCB</term><def><p id="Par6">Calcium channel blocker</p></def></def-item><def-item><term>CHEP</term><def><p id="Par7">Canadian Hypertension Education Program</p></def></def-item><def-item><term>CTD</term><def><p id="Par8">Chlorthalidone</p></def></def-item><def-item><term>HCTZ</term><def><p id="Par9">Hydrochlorothiazide</p></def></def-item><def-item><term>HDFP</term><def><p id="Par10">Hypertension Detection and Follow-Up Program</p></def></def-item><def-item><term>MRFIT</term><def><p id="Par11">Multiple Risk Factor Intervention Trial</p></def></def-item><def-item><term>NICE</term><def><p id="Par12">National Institute for Health and Care Excellence</p></def></def-item><def-item><term>NIH</term><def><p id="Par13">National Institutes of Health</p></def></def-item><def-item><term>PWV</term><def><p id="Par14">Pulse wave velocity</p></def></def-item><def-item><term>SHEP</term><def><p id="Par15">Systolic Hypertension in the Elderly Program</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Not applicable.</p><sec id="FPar1"><title>Funding</title><p id="Par25">There is no funding for this work.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par26">Not applicable.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>All authors contributed equally to the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par27">Not applicable.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par28">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par29">Authors are affiliated to Ipca Laboratories Limited and are involved in research studies on chlorthalidone.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par30">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>GC</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Chung</surname><given-names>WJ</given-names></name><name><surname>Youn</surname><given-names>HJ</given-names></name><name><surname>Cho</surname><given-names>EJ</given-names></name><name><surname>Sung</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active-controlled, phase 4, randomized trial</article-title><source>Clin Hypertens</source><year>2017</year><volume>23</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/s40885-017-0074-0</pub-id><pub-id pub-id-type="pmid">28879040</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodman</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>C</given-names></name><name><surname>Lockette</surname><given-names>W</given-names></name></person-group><article-title>Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis</article-title><source>Hypertension</source><year>2010</year><volume>56</volume><issue>3</issue><fpage>463</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.110.154476</pub-id><pub-id pub-id-type="pmid">20625077</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sica</surname><given-names>DA</given-names></name></person-group><article-title>Chlorthalidone - a renaissance in use?</article-title><source>Expert Opin Pharmacother</source><year>2009</year><volume>10</volume><issue>13</issue><fpage>2037</fpage><lpage>2039</lpage><pub-id pub-id-type="doi">10.1517/14656560903158956</pub-id><pub-id pub-id-type="pmid">19663607</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messerli</surname><given-names>FH</given-names></name><name><surname>Makani</surname><given-names>H</given-names></name><name><surname>Benjo</surname><given-names>A</given-names></name><name><surname>Romero</surname><given-names>J</given-names></name><name><surname>Alviar</surname><given-names>C</given-names></name><name><surname>Bangalore</surname><given-names>S</given-names></name></person-group><article-title>Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>57</volume><issue>5</issue><fpage>590</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2010.07.053</pub-id><pub-id pub-id-type="pmid">21272751</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017. Epub ahead of print. 10.1161/HYP.0000000000000065.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>AA</given-names></name><name><surname>Daskalopoulou</surname><given-names>SS</given-names></name><name><surname>Dasgupta</surname><given-names>K</given-names></name><etal/></person-group><article-title>Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults</article-title><source>Can J Cardiol</source><year>2017</year><volume>33</volume><issue>5</issue><fpage>557</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.cjca.2017.03.005</pub-id><pub-id pub-id-type="pmid">28449828</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Clinical Guideline Centre (UK)</collab></person-group><source>Hypertension: the clinical Management of Primary Hypertension in adults: update of clinical guidelines 18 and 34</source><year>2011</year><publisher-loc>London</publisher-loc><publisher-name>Royal College of Physicians (UK)</publisher-name></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>BJ</given-names></name><name><surname>Jang</surname><given-names>SW</given-names></name><name><surname>Choi</surname><given-names>KY</given-names></name><etal/></person-group><article-title>Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-na&#x000ef;ve patients of hypertension</article-title><source>Hypertens Res</source><year>2013</year><volume>36</volume><issue>1</issue><fpage>79</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/hr.2012.143</pub-id><pub-id pub-id-type="pmid">23034468</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82(5):1616&#x02013;28.</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>ME</given-names></name><name><surname>Carter</surname><given-names>BL</given-names></name><name><surname>Basile</surname><given-names>JN</given-names></name></person-group><article-title>All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective</article-title><source>J Clin Hypertens (Greenwich)</source><year>2009</year><volume>11</volume><issue>1</issue><fpage>5</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7176.2008.00009.x</pub-id><pub-id pub-id-type="pmid">19125852</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pareek</surname><given-names>A</given-names></name><name><surname>Basavanagowdappa</surname><given-names>H</given-names></name><name><surname>Zawar</surname><given-names>S</given-names></name><etal/></person-group><article-title>A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension</article-title><source>Expert Opin Pharmacother</source><year>2009</year><volume>10</volume><issue>10</issue><fpage>1529</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1517/14656560902991514</pub-id><pub-id pub-id-type="pmid">19514864</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pareek</surname><given-names>AK</given-names></name><name><surname>Messerli</surname><given-names>FH</given-names></name><name><surname>Chandurkar</surname><given-names>NB</given-names></name><etal/></person-group><article-title>Efficacy of low-dose Chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring</article-title><source>J Am Coll Cardiol</source><year>2016</year><volume>67</volume><issue>4</issue><fpage>379</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2015.10.083</pub-id><pub-id pub-id-type="pmid">26821625</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group</collab></person-group><article-title>Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)</article-title><source>JAMA</source><year>2002</year><volume>288</volume><issue>23</issue><fpage>2981</fpage><lpage>2997</lpage><pub-id pub-id-type="doi">10.1001/jama.288.23.2981</pub-id><pub-id pub-id-type="pmid">12479763</pub-id></element-citation></ref></ref-list></back></article>